Paul V. Ward

Array ( [id] => 18003405 [patent_doc_number] => 20220362171 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => USE OF TAPINAROF FOR THE TREATMENT OF CHRONIC PLAQUE PSORIASIS [patent_app_type] => utility [patent_app_number] => 17/871663 [patent_app_country] => US [patent_app_date] => 2022-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52741 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17871663 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18020542 [patent_doc_number] => 20220372041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => QUINOXALINE DERIVATIVES [patent_app_type] => utility [patent_app_number] => 17/866672 [patent_app_country] => US [patent_app_date] => 2022-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24822 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 536 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17866672 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18019128 [patent_doc_number] => 20220370627 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => COMPOSITIONS AND METHODS FOR TARGETED PROTEIN STABILIZATION BY REDIRECTING ENDOGENOUS DEUBIQUITINASES [patent_app_type] => utility [patent_app_number] => 17/864382 [patent_app_country] => US [patent_app_date] => 2022-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5591 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17864382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18184627 [patent_doc_number] => 20230045357 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => BIARYLMETHYL HETEROCYCLES [patent_app_type] => utility [patent_app_number] => 17/861809 [patent_app_country] => US [patent_app_date] => 2022-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 134693 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17861809 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18215225 [patent_doc_number] => 11590138 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-28 [patent_title] => Topical treatment of vitiligo by a jak inhibitor [patent_app_type] => utility [patent_app_number] => 17/860884 [patent_app_country] => US [patent_app_date] => 2022-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 64 [patent_figures_cnt] => 64 [patent_no_of_words] => 31414 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17860884 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19840109 [patent_doc_number] => 12252478 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Crystalline forms of N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide [patent_app_type] => utility [patent_app_number] => 17/858701 [patent_app_country] => US [patent_app_date] => 2022-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 9120 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17858701 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19840110 [patent_doc_number] => 12252479 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Crystalline forms OF N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide [patent_app_type] => utility [patent_app_number] => 17/858713 [patent_app_country] => US [patent_app_date] => 2022-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 9119 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17858713 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18824354 [patent_doc_number] => 11839617 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-12 [patent_title] => Theramutein modulators [patent_app_type] => utility [patent_app_number] => 17/857492 [patent_app_country] => US [patent_app_date] => 2022-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 23874 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 162 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17857492 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19026307 [patent_doc_number] => 11925647 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-12 [patent_title] => Theramutein modulators [patent_app_type] => utility [patent_app_number] => 17/857478 [patent_app_country] => US [patent_app_date] => 2022-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 23869 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17857478 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17944308 [patent_doc_number] => 20220331325 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CHRONIC LUNG ALLOGRAFT DYSFUNCTION [patent_app_type] => utility [patent_app_number] => 17/854443 [patent_app_country] => US [patent_app_date] => 2022-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12931 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17854443 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18418620 [patent_doc_number] => 20230173078 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => SMARCA DEGRADERS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/851528 [patent_app_country] => US [patent_app_date] => 2022-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 182870 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17851528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19121009 [patent_doc_number] => 11964979 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-23 [patent_title] => Camsylate salts of triazolopyrazine derivatives [patent_app_type] => utility [patent_app_number] => 17/849784 [patent_app_country] => US [patent_app_date] => 2022-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 63 [patent_no_of_words] => 9908 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 181 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17849784 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19316638 [patent_doc_number] => 20240238178 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => COMPOSITION COMPRISING AHAS AND/OR BHAS WHICH IS STABILIZED BY A COMBINATION OF MONOALKYL OR DIALKYL ISOSORBIDE, POLYETHYLENE GLYCOL-POLYPROPYLENE GLYCOL ETHER AND TWO HYDROGENATED OR NON-HYDROGENATED POLYOXYETHYLENATED PLANT OILS [patent_app_type] => utility [patent_app_number] => 18/559805 [patent_app_country] => US [patent_app_date] => 2022-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5222 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18559805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19624087 [patent_doc_number] => 12162891 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-10 [patent_title] => Glutamate transporter activators and methods using same [patent_app_type] => utility [patent_app_number] => 17/847490 [patent_app_country] => US [patent_app_date] => 2022-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 33 [patent_no_of_words] => 19532 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 555 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17847490 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18091257 [patent_doc_number] => 20220409598 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => METHOD OF CONTROLLING BLOOD SUGAR LEVEL AND TREATMENT OF DIABETES AND RELATED CONDITIONS [patent_app_type] => utility [patent_app_number] => 17/843587 [patent_app_country] => US [patent_app_date] => 2022-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17117 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17843587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19104620 [patent_doc_number] => 11957693 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-16 [patent_title] => Combination MCL-1 inhibitors with anti-cancer agents [patent_app_type] => utility [patent_app_number] => 17/836444 [patent_app_country] => US [patent_app_date] => 2022-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 22010 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17836444 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18352302 [patent_doc_number] => 20230140413 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases [patent_app_type] => utility [patent_app_number] => 17/831049 [patent_app_country] => US [patent_app_date] => 2022-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44566 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17831049 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20756194 [patent_doc_number] => 12648941 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-09 [patent_title] => Piperidine urea derivatives for use as inotropic agents [patent_app_type] => utility [patent_app_number] => 18/566301 [patent_app_country] => US [patent_app_date] => 2022-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 5891 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18566301 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20756194 [patent_doc_number] => 12648941 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-09 [patent_title] => Piperidine urea derivatives for use as inotropic agents [patent_app_type] => utility [patent_app_number] => 18/566301 [patent_app_country] => US [patent_app_date] => 2022-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 5891 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18566301 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18336642 [patent_doc_number] => 20230128591 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENT [patent_app_type] => utility [patent_app_number] => 17/830682 [patent_app_country] => US [patent_app_date] => 2022-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12200 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17830682 [rel_patent_id] =>[rel_patent_doc_number] =>)